Publication: Potential chemotherapeutic targets for Japanese encephalitis: Current status of antiviral drug development and future challenges
Issued Date
2015-01-01
Resource Type
ISSN
17447631
14728222
14728222
Other identifier(s)
2-s2.0-84941756475
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Opinion on Therapeutic Targets. Vol.19, No.10 (2015), 1379-1395
Suggested Citation
Tomohiro Ishikawa, Eiji Konishi Potential chemotherapeutic targets for Japanese encephalitis: Current status of antiviral drug development and future challenges. Expert Opinion on Therapeutic Targets. Vol.19, No.10 (2015), 1379-1395. doi:10.1517/14728222.2015.1065817 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/35591
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Potential chemotherapeutic targets for Japanese encephalitis: Current status of antiviral drug development and future challenges
Author(s)
Other Contributor(s)
Abstract
© 2015 Informa UK, Ltd. Introduction: Japanese encephalitis (JE) remains a public health threat in Asia. Although several vaccines have been licensed, ∼ 67,900 cases of the disease are estimated to occur annually, probably because the vaccine coverage is low. Therefore, effective antiviral drugs are required to control JE. However, no licensed anti-JE drugs are available, despite extensive efforts to develop them.Areas covered: We provide a general overview of JE and JE virus, including its transmission cycle, distribution, structure, replication machinery, immune evasion mechanisms and vaccines. The current situation in antiviral drug development is then reviewed and future perspectives are discussed.Expert opinion: Although the development of effective anti-JE drugs is an urgent issue, only supportive care is currently available. Recent progress in our understanding of the viral replication machinery and immune evasion strategies has identified new targets for anti-JE drug development. To date, most candidate drugs have only been evaluated in single-drug formulations, and efficient drug delivery to the CNS has virtually not been considered. However, an effective anti-JE treatment is expected to be achieved with multiple-drug formulations and a targeted drug delivery system in the near future.